🇺🇸

US SEC Filing Intelligence

· daily

USA Insider Trading Pulse — August 13, 2026

Today's insider trading pulse reveals a pronounced dichotomy: aggressive insider buying at deeply discounted valuations in Embecta Corp. and Amrize Ltd. contrasts with massive, pre-planned selling by Sea Ltd's entire C-suite totaling over $52 million. The data shows a clear sector rotation, with insiders at financial and industrial firms like Global Medical REIT and Blue Bird Corp signaling confidence, while technology and specialty finance executives, particularly at Camtek and Associated Banc-Corp, are reducing exposure. A notable cluster of 10% owner selling in Tredegar Corp by three family members suggests coordinated estate planning or a bearish outlook on the packaging sector. The most actionable signal is the coordinated insider buying spree at Amrize Ltd, where six executives purchased shares on the same day, indicating strong internal conviction. Overall, the data points to a market where insiders are betting on value and turnaround stories while taking profits in high-growth and cyclical names.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 13, 2026

This digest covers 11 SEC filings related to M&A and SPAC activity, revealing a bifurcated market. On one side, two major industrial acquisitions closed: Parker-Hannifin's $9.25B purchase of Filtration Group, funded with $7.75B in new debt, and Global Net Lease's $535M acquisition of Modiv Industrial, which is expected to be immediately accretive. These signal continued appetite for scale and strategic consolidation. Conversely, the SPAC sector shows significant distress: Artius II Acquisition Corp. announced liquidation, while several other SPACs (Athena Technology, Digital Asset Acquisition, Inflection Point) filed extensions or terminated agreements, highlighting a challenging environment for de-SPAC transactions. A key risk flag is NOCERA, INC., which filed an 8-K indicating a change in control and potential delisting, suggesting a distressed sale. The overall theme is a divergence between high-quality, accretive M&A and struggling blank-check companies facing liquidation or deal failure.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 13, 2026

Overnight filings reveal a bifurcated market with aggressive growth stories in niche sectors (BBB Foods, Elmet Group) offset by deep value destruction in biotech and SPACs. A massive coordinated insider sell-off at Takeda Pharmaceutical ($7.5M+ across 10 executives) signals deep concern within the C-suite, while a contrarian insider buying spree at Hepion Pharmaceuticals ($725K) suggests a potential turnaround play. The most significant capital event is SoundHound AI's proposed acquisition of LivePerson, which could reshape the conversational AI landscape. Key period-over-period trends show revenue growth is not translating to profitability, with 4 out of 5 reporting companies showing widening net losses despite top-line expansion. The energy sector shows mixed signals with enCore Energy's uranium deliveries up 38.6% but extraction costs soaring, while the SPAC market shows continued distress with Newbury Street's net income collapsing 81.5%.

40 high priority 10 medium 50 total filings
· daily

DHS Homeland Security Contracts — August 12, 2026

This digest covers a single $105.6 million civilian contract from the Department of Homeland Security (DHS) to Jacobs Engineering Group Inc. (parent STG LLC) for construction management advisory services on 11 border patrol station projects. The contract is entirely civilian, with no defense exposure, and signals sustained DHS investment in border security infrastructure under current immigration enforcement priorities. The highest-conviction signal is neutral: the firm-fixed-price structure provides revenue visibility but carries execution risk on 11 design-build projects. Key watch items include option exercises that could expand the contract to $162.3 million and potential policy shifts affecting DHS border funding.

1 total filings
· daily

VA Healthcare & Services Contracts — August 12, 2026

This digest covers a single, large civilian contract from the Department of Veterans Affairs (VA) to Leidos Holdings (via QTC Medical Services) valued at $113.9 million for medical disability examinations. The contract is entirely civilian, with no defense-related exposure, and carries a strong bullish signal due to its firm-fixed-price structure and 92% outlay rate, indicating near-complete revenue realization and low execution risk. The highest-conviction signal is Leidos' competitive win under full-and-open competition, reinforcing its moat in VA medical evaluation services. A key risk is the single-contract concentration on Leidos, which creates dependency on VA's stable but non-growing budget for this mandated service line.

1 total filings
· daily

New Federal Contractors — August 12, 2026

This digest covers $615.8 million in new federal contract obligations from August 12, 2026, with a 1/4 defense-related split (the DHS/CBP award to Jacobs Engineering is the closest to defense, given border security alignment). The dominant sector theme is civilian healthcare and administrative services, led by Palmetto GBA's $212.5M CMS contract (low outlay raises execution questions) and Roche's $183.8M BARDA R&D award (cost-no-fee limits margin). The highest-conviction signal is Leidos' QTC Medical Services $113.9M VA disability exam contract, with 92% outlay indicating near-complete revenue realization and strong competitive positioning. Key risk: Palmetto GBA's contract expires September 2024 with only 7% disbursed, signaling potential funding stagnation or re-compete vulnerability.

4 total filings
· daily

Significant Contract Modifications ($10M+) — August 12, 2026

This digest covers four significant contract modifications totaling $615.8 million, with only one of four being defense-related (the Department of Homeland Security award to Jacobs Engineering), indicating a civilian-heavy procurement period. The dominant sector theme is healthcare and social services, with two large HHS awards (Palmetto GBA at $212.5M and Roche at $183.8M) and a VA award to Leidos (QTC Medical Services) at $113.9M. The highest-conviction signal is the bullish VA award to Leidos, where 92% of the $113.9M has already been outlaid, reflecting strong execution and stable demand. A key risk is the large outlay gap in the Palmetto GBA contract ($212.5M obligated but only $14.6M outlaid), which may signal execution or funding issues ahead of its September 2024 expiration.

4 total filings
· daily

Contract Deobligations Alert — August 12, 2026

The August 12, 2026 contract deobligations digest reveals $615.8 million in total obligations, with only 1 of 4 contracts defense-related, underscoring a civilian-heavy federal procurement environment. The dominant theme is healthcare and administrative services, with HHS (CMS and BARDA) accounting for $396.4 million (64%) of the total, while DHS/CBP and VA contribute $105.6 million and $113.9 million respectively. The highest-conviction signal is Leidos' (via QTC Medical Services) $113.9 million VA disability exam contract, which shows 92% outlay and a bullish outlook due to mandated demand. Key risks include Jacobs' high execution risk on a firm-fixed-price border infrastructure contract and Palmetto GBA's low outlay rate (7%) despite a $212.5 million obligation, suggesting potential funding or performance issues. Investors should watch for option exercises on Jacobs' contract and re-competition of Palmetto GBA's CMS contract post-2024.

4 total filings
· daily

Contract Option Exercises — August 12, 2026

The four contracts analyzed represent $615.8 million in total obligations, with a 1/4 defense-related split (all civilian agencies: HHS, VA, DHS). The dominant theme is stable, long-duration civilian agency spending on healthcare administration (Palmetto GBA at $212.5M), biodefense R&D (Roche at $183.8M), veteran medical exams (Leidos/QTC at $113.9M), and border security infrastructure (Jacobs at $105.6M). The highest-conviction signal is Leidos' near-complete revenue realization (92% outlay rate) on its VA medical exam contract, indicating strong execution and recurring demand. Key risk: Jacobs' firm-fixed-price border station contract carries high execution risk on 11 design-build projects, with potential cost overruns.

4 total filings
· daily

Federal Professional Services Contracts — August 12, 2026

The sole contract in this digest is a $105.6 million firm-fixed-price BPA call awarded to Jacobs Engineering Group Inc. (via subsidiary STG LLC) from the Department of Homeland Security's Customs and Border Protection for construction management advisory services on 11 border patrol station projects across four states. This is a 100% civilian contract, with zero defense exposure, signaling a continuation of DHS investment in border security infrastructure through 2031. The highest-conviction signal is the neutral-to-bullish multi-year revenue visibility for Jacobs, though the fixed-price structure introduces high execution risk on 11 large design-build projects. Key watch items include option exercises to bring total value to $162.3 million and any shifts in border security policy that could impact future DHS contract obligations.

1 total filings
· daily

All HHS Contracts — August 12, 2026

The two HHS contracts analyzed total $396.4 million in obligations, with a 50/50 defense-civilian split (one BARDA biodefense contract, one CMS administrative contract). The dominant theme is stable, multi-decade funding for healthcare administration and biodefense R&D, but both contracts show low execution velocity—Palmetto GBA's $212.5M CMS contract has only $14.6M outlaid over 16 years, and Roche's $183.8M BARDA contract is cost-no-fee, limiting profit contribution. The highest-conviction signal is the potential re-compete of Palmetto GBA's contract after September 2024, which could disrupt a long-standing incumbent relationship. Key risk: the large gap between obligated and outlaid funds for Palmetto GBA suggests either delayed revenue recognition or program under-execution, warranting close monitoring.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — August 12, 2026

This digest covers $615.8 million in total obligations across four contracts, with only one of four being defense-related (25%), reflecting a civilian-heavy mix dominated by HHS ($396.4M combined) and DHS ($105.6M). The highest-conviction signal is the Leidos Holdings (via QTC Medical Services) $113.9M VA contract, which is 92% outlaid, indicating near-complete revenue realization and strong execution in a stable, legally mandated program. The dominant theme is stable, long-duration civilian agency spending on healthcare administration and biodefense R&D, but the Palmetto GBA contract's massive $197.9M gap between obligated and outlaid funds raises questions about revenue recognition and execution pace. Key risk: the Jacobs Engineering $105.6M firm-fixed-price border infrastructure contract carries high pricing risk given the 11-project scope and potential for cost overruns.

4 total filings
· daily

High-Value Federal Grants ($5M+) — August 12, 2026

This digest covers $615.8 million in high-value federal grants, with a 1:3 defense-to-civilian split, dominated by civilian health agencies (HHS and VA). The highest-conviction signal is a bullish one for Leidos Holdings via its QTC Medical Services subsidiary, which secured a $113.9 million VA contract with a 92% outlay rate, indicating strong execution and recurring revenue. The dominant sector theme is stable, long-term civilian healthcare administration and R&D, with Palmetto GBA's $212.5 million CMS contract and Roche's $183.8 million BARDA award providing multi-year visibility. Key risks include execution risk on Jacobs Engineering's $105.6 million fixed-price DHS border contract and the large gap between obligated and outlayed funds on the Palmetto GBA contract, which may signal funding delays or underperformance.

4 total filings
· daily

General Federal Contracts — August 12, 2026

This digest covers $615.8 million in total obligations across four civilian agency contracts, with only one of four being defense-related (VA), underscoring a healthcare and homeland security bias. The highest-conviction signal is Leidos Holdings' $113.9 million VA medical exam win (92% outlaid), indicating strong execution and recurring revenue from a mandated program. The dominant theme is stable, long-duration HHS funding (Palmetto GBA, Roche) offset by execution risk in DHS border infrastructure (Jacobs Engineering). A key risk is the $197.9 million outlay gap on Palmetto GBA's 16-year contract, suggesting potential funding or performance delays. Overall, the digest points to civilian healthcare and border security as durable pockets, but with limited defense exposure and no clear competitive moats.

4 total filings
· daily

S&P 500 Technology Sector SEC Filings — August 12, 2026

The 16 filings from the S&P 500 Technology sector reveal a powerful bifurcation: AI infrastructure leaders like Cisco are delivering record revenue and surging AI orders, while insider selling at KLA, Datadog, and CrowdStrike signals caution at elevated valuations. Cisco's standout Q4 FY2026 results—revenue up 18% YoY to $17.3B and AI orders of $4B—underscore the AI capex boom, but flat services revenue and cash flow suggest margin pressure. Insider activity is a dominant theme: KLA's CEO and President sold a combined $24M, CrowdStrike's CEO sold $1.07M, and Datadog's CTO sold $2.09M, all under 10b5-1 plans, while Cisco executives had routine tax-withholding sales. The absence of dividend or buyback changes across filings points to reinvestment over shareholder returns. Key risks include KLA's heavy insider selling, CrowdStrike's CEO sales amid competitive pressure, and Palantir's large insider gift. Opportunities center on Cisco's AI momentum and strong guidance, while Synopsys's GC departure is a minor governance watch item.

14 high priority 2 medium 16 total filings
· daily

Nasdaq 100 Stocks SEC Filings — August 12, 2026

The 23 filings from NASDAQ-100 constituents reveal a market bifurcated between AI infrastructure hyperscalers and mature tech stalwarts. CoreWeave's 10-Q shows explosive revenue growth (112% YoY) but a sharp swing to operating losses, massive debt accumulation ($35B), and heavy customer concentration, signaling a high-risk, high-reward AI buildout. In contrast, Cisco's record Q4 FY2026 results (revenue +18% YoY, EPS +52%) and raised AI infrastructure guidance ($9.3B in FY orders) demonstrate profitable AI monetization. Insider activity is a key signal: CoreWeave's Chief Development Officer sold nearly $11M in shares via 10b5-1 plans, while Meta's COO and Qualcomm's CFO also executed sales, contrasting with routine tax withholdings at Cisco and Amgen. Capital allocation trends show Cisco generating strong cash flows, while Intel raised $23B via a dilutive equity offering to fund its turnaround. The period-over-period data highlights a clear winner in networking (Cisco) and a capital-intensive, cash-burning challenger in cloud compute (CoreWeave).

16 high priority 7 medium 23 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — August 12, 2026

The August 12, 2026, batch of 50 SEC filings is dominated by routine, passive institutional ownership updates (13G filings), with Norges Bank, AQR Capital Management, and Hotchkis & Wiley being the most active filers. The most significant actionable signals are two complete exits by activist-adjacent funds (Iroquois from XWELL, 683 Capital from Perceptive Capital Solutions) and one significant restructuring by HHCF in Katapult Holdings, converting preferred equity into debt and common stock. While most filings show no change in ownership or intent, the aggregate data reveals a strong, passive institutional presence in sectors like REITs (Kilroy, Federal Realty, Digital Realty, BXP) and large-cap tech (Atlassian, Workday, Duolingo). The key takeaway is a lack of new activist campaigns, but the exits and restructuring provide clear, actionable signals of changing investor conviction in specific names. The period-over-period data is limited, as most filings are amendments with no change or are initial filings, but the few changes (Vanguard increasing in H&R Block, Norges Bank shifting composition in New Oriental) offer subtle clues of institutional accumulation and rebalancing.

2 high priority 48 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — August 12, 2026

The six filings from the S&P 500 Financials sector reveal a mixed picture of capital management and insider sentiment. A dominant theme is the active use of capital markets by major institutions: JPMorgan Chase reported a massive $18.07B portfolio with significant options activity, while American Express created a new $1.6B preferred share series to bolster its capital structure. However, this activity is contrasted by notable insider selling, with the President of Allstate executing a large net sale of ~$9.7M worth of stock after exercising options, and an Aflac director making a smaller sale. The T. Rowe Price OHA Select Private Credit Fund's tender offer, which saw only 57.4% participation and was settled via promissory notes, signals potential liquidity or valuation concerns in the private credit space. U.S. Bancorp's 13F filing, focused on non-U.S. equities, shows a more conservative, diversified portfolio. The overall sentiment is cautious, with capital being raised or returned to shareholders through specific mechanisms, while insiders at two major insurers are reducing their exposure, warranting close monitoring for broader sector trends. No period-over-period comparisons were available in these filings to establish growth or margin trends. No forward-looking guidance was provided in these filings to build a catalyst calendar. No capital allocation changes (dividends, buybacks) were announced in these filings. No M&A transactions were reported in these filings. No financial ratios or operational metrics were provided in these filings. No scheduled events were mentioned in these filings.

4 high priority 2 medium 6 total filings